Executive team

Eyenovia leadership has deep ophthalmic and pharmaceutical development expertise at the management
and board level, with a strong advisory panel of clinical experts and scientists.

Sean_Ianchulev_2

SEAN IANCHULEV, MD MPH

CEO and President

Bio

Dr. Ianchulev is a prolific inventor, innovator, physician-executive and public health expert with deep life-science and medical technology expertise. He has been at the forefront of medical products and technologies which have transformed the ophthalmic field and impacted medical care for thousands of patients. He is currently a Professor of Ophthalmology at the New York Eye and Ear Infirmary and sits on the Boards of Iantech Medical, Kurobe Pharmaceuticals and The American Society of Cataract and Refractive Surgery Foundation. Dr. Ianchulev spent five years at Genentech where headed the ophthalmology research group and directed the development and FDA approval of Lucentis, the most successful specialty biologic in the field of ophthalmology with more than $4B of annual sales. Dr. Ianchulev completed his MD at Harvard Medical School and his MPH, Health Policy, Finance, and Management at the Harvard School of Public Health.

ginger_update4

GINGER CLASBY

VP of Clinical Operations

Bio

Ginger Clasby has worked in the field of regulated medical products during most of her career. Most recently she served as Vice President, Clinical & Regulatory Affairs/Quality Assurance at Transcend Medical, an early-stage, venture-backed company developing novel products for management of glaucoma, which was acquired by Alcon. In that position, she was responsible for overseeing clinical operations and regulatory processes for the company’s trials in the US, Europe and Latin America, as well as worldwide regulatory affairs, quality assurance and compliance activities. Previously, Ginger worked with ophthalmic device companies American Medical Optics and Optical Radiation Corporation in various roles in the areas of Clinical Affairs, Manufacturing Operations and Marketing/Sales. She was also a pivotal executive with Promedica International, a contract research organization, where she worked closely with clients to establish the company as a respected provider of clinical research services within the ophthalmic and medical device market sectors. She holds the MS degree in Industrial Engineering from Arizona State University and BS degrees in Mathematics & Physics from Guilford College. She serves on the University of California-Irvine Extension Life Science Advisory Committee.

Luke_Clauson

LUKE CLAUSON

R&D, Engineering

Bio

Luke Clauson started his engineering career at Cardica where he eventually directed product development for the core anastomotic business. In 2004, he founded Innovative Drive, a medical device focused engineering development company that has helped businesses of all sizes conceptualize and bring products to market. Since, Luke was a VP of R&D/OPS at Transcend Medical and more recently as a technology co-founder at IanTech, Inc.

John Galdofo

JOHN GANDOLFO

Chief Financial Officer

Bio

John Gandolfo brings more than 30 years of experience as a finance executive of rapidly growing private and publicly held companies in the life sciences, healthcare and medical device areas. Prior to joining Eyenovia, John was the Chief Financial Officer of Xtant Medical – a global developer and manufacturer of biologics and implants for orthopedic and spine applications. Previously, he served as the Chief Financial Officer for Progenitor Cell Therapy, a leading manufacturer of stem cell therapies, and as the CFO of Power Medical Interventions, a publicly held developer and manufacturer of computerized surgical systems. He was also the CFO of several other public and private companies, namely Bioject Medical Technologies, Capital Access Network, Impath and Medical Resources.

Lee Kram, MD_3

LEE KRAMM, MD

Regulatory Affairs

Bio

Dr. Lee Kramm is a board certified Ophthalmologist with a Masters' degree in Biomedical Engineering. He earned his graduate degree from the Tulane University School of Engineering and his medical degree from the University of Miami School of Medicine. Following medical school he received general and surgical training in Ophthalmology from the Rocky Mountain Lions Eye Institute at the University of Colorado in Denver. Dr. Kramm served for five years as a medical officer and scientific reviewer in the Division of Ophthalmic, Neurological and ENT Devices in the Center for Devices and Radiological Health, FDA. In his position as a medical officer at FDA, Dr. Kramm reviewed a variety of ophthalmic devices and served on several internal FDA working groups whose goal was to improve and bring consistency to premarket regulation and clinical evaluation. During his tenure at FDA, Dr. Kramm reviewed pre-IDEs, IDEs, PMAs, 510(k)s, Humanitarian Use Designations (HUD), Humanitarian Device Exemptions (HDE), Class I/II device recalls, combination products and requests for designation (RFD).

Mike Rowe

MIKE ROWE

VP of Marketing

Bio

Michael Rowe brings his extensive experience in ophthalmic drug and device marketing and development to Eyenovia’s mission of “Making it Possible™.” Prior to joining Eyenovia, Michael was responsible for leading the global glaucoma product strategy for Allergan and most recently the U.S. launch of Rhopressa® for Aerie Pharmaceuticals. For Michael, “Making it Possible™” means ensuring that diseases such as progressive myopia are finally addressed because of Eyenovia’s micro-dose technology.

Board of Directors

FredV3

FRED ESHELMAN, PHD

Chairman of the Board

Bio

Fred Eshelman is Chairman of The Medicines Company (MDCO), and is the founder of Eshelman Ventures LLC, an investment company primarily interested in private healthcare companies. Previously he founded and served as CEO and Executive Chairman of Pharmaceutical Product Development (PPDI, NASDAQ) prior to the sale of the company to private equity interests. After PPD he served as Founding Chairman and largest shareholder of Furiex Pharmaceuticals (FURX, NASDAQ), a company which licensed and rapidly developed new medicines.

Sean_Ianchulev_2

SEAN IANCHULEV, MD MPH

CEO and President

Bio

Dr. Ianchulev is a prolific inventor, innovator, physician-executive and public health expert with deep life-science and medical technology expertise. He has been at the forefront of medical products and technologies which have transformed the ophthalmic field and impacted medical care for thousands of patients. He is currently a Professor of Ophthalmology at the New York Eye and Ear Infirmary and sits on the Boards of Iantech Medical, Kurobe Pharmaceuticals and The American Society of Cataract and Refractive Surgery Foundation. Dr. Ianchulev spent five years at Genentech where headed the ophthalmology research group and directed the development and FDA approval of Lucentis, the most successful specialty biologic in the field of ophthalmology with more than $4B of annual sales. Dr. Ianchulev completed his MD at Harvard Medical School and his MPH, Health Policy, Finance, and Management at the Harvard School of Public Health.

CurtV3

CURT LABELLE, MD MBA

Director

Bio

Dr. LaBelle has been investing in and working with healthcare companies for over 16 years. He is the managing partner of the Global Health Investment Fund which invests in companies developing products for conditions that disproportionately affect the developing world. He has served as a Board member or observer for many successful companies, including KAI Pharmaceuticals (sold to Amgen), Sirion Therapeutics (sold to B&L and Alcon), Impulse Monitoring (sold to NuVasive), TransMolecular (sold to Morphotek), Estech (sold to Atricure), Coherex (sold to J&J), Exagen Diagnostics, SafeOp among others. Dr. Labelle obtained his MD from Columbia University’s College of Physicians and Surgeons, MBA from Columbia University Business School and Bachelors in Economics from Brigham Young University.

image001

KENNETH LEE

Director

Bio

Mr. Lee is life science industry veteran with more than 30 years of experience in advising biotechnology and pharmaceutical companies globally. Currently Mr. Lee is a General Partner of Hatteras Venture Partners, LLC, a venture capital fund focusing on life science companies since January 2003. Previously he was President of A.M. Pappas & Associates, LLC, following 29 years with Ernst & Young LLP, where he was most recently Managing Director of the firm’s health sciences corporate finance group, and at one time served as the National Director of the Life Sciences Practice. Mr. Lee serves on the boards of Aralez Pharmaceuticals, Inc. (Nasdaq: ARLZ) and BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX). Mr. Lee received a B.A. from Lenoir-Rhyne College and an M.B.A. from the University of North Carolina at Chapel Hill.

Maher

CHARLES MATHER

Director

Bio

Mr. Mather is a seasoned investment banking professional with more than 30 years of experience in traditional as well as alternative capital markets. He is currently Managing Director, Co-Head of Equity Capital Markets at BTIG, LLC. From 2009 to 2015 he was the Head of Private and Alternative Capital and Co-Head of Equity Capital Markets at Janney Montgomery Scott, LLC. Mr. Mather was the head of the Structured Equity Group at Jefferies Group Inc. and held various senior investment banking positions at Cowen and Company, including as Co-Head of the Private Equity Group. Mr. Mather serves on the board of Tonix Pharmaceuticals Holdings Corp. (Nasdaq: TNXP) and Wentz LLC. Mr. Mr. Mather received a B.A. in History from Brown University and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.

ErnestV3

ERNEST MARIO, PHD

Director

Bio

Dr. Mario has been a leader in the pharmaceutical industry for more than 40 years.  He currently serves as Chairman of Capnia Inc. and Chimerix Inc., and is a Venture Partner with Pappas Ventures.  Dr. Mario served as Chairman and Chief Executive Officer of Reliant Pharmaceuticals, Inc., a privately held company that was acquired by GlaxoSmithKline in 2008. Dr. Mario also served as Chairman and Chief Executive Officer of ALZA Corporation, a research-based pharmaceutical company acquired by Johnson & Johnson in 2001.

Anthony Sun

ANTHONY SUN, MD MPH

Director

Bio

Dr. Sun has played an active role across the life science industry since 2002 and currently serves as the Executive Director of Zeno Pharmaceuticals. Froom 2002 until 2015, Dr. Sun was at Aisling Capital, a private equity firm dedicated to life sciences, during which he held multiple positions most recently as partner. Dr. Sun serves on the board of Versartis, Inc. (Nasdaq: VSAR), Immusoft Corporation and several other private companies. Dr. Sun holds a B.S. in Electrical Engineering from Cornell University, an M.D. from Temple University School of Medicine, an M.B.A. from The Wharton School at the University of Pennsylvania, trained in internal medicine at the Hospital of the University of Pennsylvania and was Board Certified in Internal Medicine.

Takemasa_rect

SHUHEI YOSHIDA

Director

Bio

Mr. Yoshida has extensive executive and operational experience in the international pharmaceutical industry. Mr. Yoshida is the Executive Vice President and Head of Corporate Strategic Planning at Senju Pharmaceutical Co., Ltd., a leading, privately owned specialty pharmaceutical research, development, manufacturing and sales company located in Osaka, Japan, with global subsidiaries, branch offices and joint venture relationships throughout the world, including in the United States, Canada, South America, Europe, Middle East, Asia and Africa.

Scientific Advisory Board

Dr. Fredrick

Douglas Fredrick, MD

Clinical Professor and board-certified ophthalmologist

Bio

Dr.Fredrick is a Clinical Professor and board-certified ophthalmologist specializing in pediatric ophthalmology and brings more than 30 years of experience at leading medical institutions. He serves as the Director of Residency Program, Vice Chair of Education and Vice Chair of Clinical Affairs at the Stanford University School of Medicine Byers Eye Institute. Prior to joining Stanford University, he was a full-time faculty member at the University of California San Francisco and Dartmouth. Dr. Fredrick is a member of the American Academy of Ophthalmology, American Academy of Pediatrics and the American Association of Pediatric Ophthalmology and Strabismus (AAPOS). He completed his ophthalmology residency at the University of California San Francisco and fellowship in pediatric ophthalmology at Boston Children’s Hospital. Dr. Fredrick has authored more than 30 publications and serves as an Invited Reviewer for Ophthalmology, The British Journal of Ophthalmology and the Journal of American Association for Pediatric Ophthalmology and Strabismus.

PamGallin

Pamela F. Gallin, M.D., F.A.C.S.

Director Emeritus, Pediatric Ophthalmology

Bio

Pamela F. Gallin, M.D., F.A.C.S. is one of the highest ranking female surgeons at NY Presbyterian where she is a Director Emeritus, Pediatric Ophthalmology and Adult Strabismus & Clinical Professor of Ophthalmology in Pediatrics NY Presbyterian-Columbia University Medical Center. She is the author of “Pediatric Ophthalmology”, a textbook used internationally. Dr. Gallin graduated from Washington University in St. Louis MD (Top 10%), AB, BS: Summa Cum Laude, Phi Beta Kappa and Tau Beta Pi (Engineers Phi Beta Kappa). Her Ophthalmology residency at The Mt. Sinai Medical Center (NY) was followed by a Heed Foundation Fellowship. She studied: Pediatric Ophthalmology (Marshall Parks, MD, Children’s National Medical Center and Dr. Philip Knapp, MD Columbia University Medical Center ), Pediatric Ophthalmic Oncology (Robert Ellsworth. MD & David Abramson, MD) and Genetics (Irene Maumenee, MD).

Dr Lin

Shan Lin , M.D.

Professor of Clinical Ophthalmology

Bio

Shan Lin is Professor of Clinical Ophthalmology at the University of California, San Francisco, and Director of the Glaucoma Service at UCSF and the Zuckerberg San Francisco General Hospital. His research interests include: 1) angle closure glaucoma; 2) glaucoma among Asians; 3) cyclodestructive procedures, and 4) the role of cataract surgery in glaucoma treatment. His leadership positions include Executive Vice President of the World Glaucoma Association, Chair of the Ambassador Committee for the American Glaucoma Society, past Chair of the American Glaucoma Society’s Patient Care Committee, past Chair of the Glaucoma Section of the Ophthalmic Technology Assessment Committee of the American Academy of Ophthalmology, past Chair of the American Glaucoma Society’s Document Review Subcommittee, and past President, Vice President and Program Chair of the Pacific Coast Oto-Ophthalmological Society (PCOOS).

Louis_R_Pasquale

Louis R. Pasquale, MD

Professor of Ophthalmology and Distinguished Scholar

Bio

Louis R. Pasquale, MD is Professor of Ophthalmology and Distinguished Scholar in Ophthalmology at Harvard Medical School. In addition to co-directing Harvard’s Glaucoma Center of Excellence, he directs the Glaucoma Service, Glaucoma Fellowship Program and the Teleretinal Program at Massachusetts Eye and Ear Infirmary.

Dt tsai

James C. Tsai, MD, MBA, FACS

Professor and Chair of Ophthalmology

Bio

Dr. James Tsai is the President of New York Eye and Ear Infirmary of Mount Sinai, America’s first and longest operating specialty hospital. He also serves as the Delafield-Rodgers Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai and System Chair of Ophthalmology for the Mount Sinai Health System. A clinician-scientist and experienced health care administrator, Tsai also serves as Chair of the Glaucoma Subcommittee of the National Eye Health Education Program Planning Committee of the National Institutes of Health (NIH), Examiner for the American Board of Ophthalmology, Chair of the Section on Ophthalmology for The New York Academy of Medicine, and Treasurer of the International Joint Commission on Allied Health Personnel in Ophthalmology (IJCAHPO).

robert_weintraub

Robert N. Weinreb, MD

Professor and Chair of Ophthalmology

Bio

Robert N. Weinreb, MD, is the Distinguished Professor and Chair of Ophthalmology at the University of California, San Diego. He is also Director of the Shiley Eye Institute, Director of the Hamilton Glaucoma Center, holder of the Morris Gleich, MD Chair of Glaucoma and is appointed as Distinguished Professor of Bioengineering. Glaucoma patients from throughout the world are referred to Dr. Weinreb for his medical and surgical expertise. Dr. Weinreb received his medical degree from Harvard Medical School. He has trained more than 140 post-doctoral Fellows in Glaucoma, including 16 Chairs and many others who hold distinguished academic positions in the United States and throughout the world. He is past President of the American Glaucoma Society (AGS), the Association for Research in Vision and Ophthalmology (ARVO), the Foundation of the American Glaucoma Society, the World Glaucoma Association (WGA), and the Pan American Glaucoma Society.

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

New York    501 Fifth Avenue, Suite 1404 New York NY 10017    +1 (917) 289-1117

[email protected]